OPEN END TURBO LONG - ZEALAND PHARMA Stock

DE000MG1YMK9

Real-time Bid/Ask 10:06:16 2024-05-23 am EDT
0.87 ^EUR / 0.92 ^EUR	+6.55%

Current month	-24.32%
1 month	+147.06%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ZEALAND PHARMA A/S

Chart OPEN END TURBO LONG - ZEALAND PHARMA

Latest news about ZEALAND PHARMA A/S

Nordic Stocks Declined Thursday; Zealand Pharma Took Biggest Hit	May. 16	DJ
Zealand Pharma A/S : Q1 2024 Financial Results	May. 16	PU
Transcript : Zealand Pharma A/S, Q1 2024 Earnings Call, May 16, 2024	May. 16
Zealand Pharma Announces Financial Results for the First Quarter of 2024	May. 16	GL

More news

Quotes 5-day view

Date	Price	Change
24-05-23	0.97	+15.48%
24-05-22	0.84	+15.07%
24-05-21	0.73	-1.35%
24-05-20	0.74	-5.13%
24-05-17	0.78	-3.70%

Delayed Quote Börse Stuttgart

Last update May 23, 2024 at 08:48 am EDT

More quotes

Static data

Product type	Knock-Out without Stop Loss
Buy / Sell	CALL
Underlying	ZEALAND PHARMA A/S
Issuer	Morgan Stanley
WKN	MG1YMK
ISIN	DE000MG1YMK9
Date issued	2024-04-09
Strike	556 kr
Maturity	Unlimited
Parity	10 : 1
Emission price	1.32 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.64 €
Lowest since issue	0.34 €
Spread	0.05 €
Spread %	5.10%

Company Profile

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.

Sector

More about the company

Ratings for Zealand Pharma A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Zealand Pharma A/S

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

613.5 DKK

Average target price

785.6 DKK

Spread / Average Target

+28.05%

Consensus